Already considered a global epidemic, human obesity continues to be on the rise. According to the Centers for Disease Control, more than 40% of the U.S. population is considered obese. The gamut of adverse health effects associated with obesity is broad, including such devastating illnesses as type 2 diabetes, coronary artery disease, stroke, sleep apnea and certain forms of cancer. Patients often suffer depression, loss of mobility, social isolation and inability to work.

With costs approaching $316 billion dollars annually in the U.S., understanding how to quell obesity will result not only in a healthier population, but could also help reduce runaway medical costs.Continue reading→

The Securities and Exchange Commission (SEC) has adopted regulatory changes to provide small public companies with a temporary exemption from Sarbanes-Oxley 404(b) compliance. 404(b) requires public companies to report on the internal controls they have in place over their financial reporting. While well-intended, this regulatory requirement has proven to reduce market capitalizations, increase audit fees, force companies to exit public markets, and reduce R&D investments in pre-revenue startups that result in fewer inventions.Continue reading→

TUCSON, Ariz., March 13, 2020 — The Critical Path Institute (C-Path) today announced it has named Sudhir Sivakumaran, Ph.D., as Executive Director of its Critical Path for Alzheimer’s Disease (CPAD) consortium effective immediately. Dr. Sivakumaran, a neuroscientist and research and development professional, has nearly 20 years combined experience in academic, pre-clinical and early clinical research and development, phase 1 and phase 2 clinical study design, data analysis and diligence and business development. He has been with C-Path since July 2019 as Associate Director for CPAD.Continue reading→

With the FDA approval of the SynCardia Systems, LLC 50cc TAH-t system a greater number of cardiac transplant eligible patients at risk of imminent death from biventricular failure now have access to total artificial heart therapy.
The 50cc TAH-t is 37.5% smaller than the 70cc device while maintaining a peak cardiac output of 7.5 liters per minute making it ideally suited for smaller statured adults and pediatric patients.Continue reading→

Az Business magazine has selected the 30 companies that will be honored at the first Arizona Business Innovation Awards. 

The 30 honorees were selected from a pool of hundreds of nominations and include AZBio and AZBio Members Xcellerate Biomedical Technologies.Continue reading→

Tech Launch Arizona (TLA) recently launched the newly developed Student Entrepreneurial Fellowship Program. The fellows comprise a team of four qualified candidates from a diverse range of backgrounds who are eager to make the most of this rare opportunity. Over the course of their employment with TLA they will work closely with the venture development team and gain valuable experience in the startup assessment and launch process.Continue reading→

On March 3, 2020, Exact Sciences Corp. (NASDAQ: EXAS) announced the completion of its acquisitions of Paradigm Diagnostics, Inc. and Viomics, Inc., two privately held companies based in Phoenix. Together, Paradigm and Viomics provide a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery, extending Exact Sciences’ lab testing and research and development capabilities.Continue reading→